Pegcetacoplan for Post-Transplant C3G, ICMPGN

At the 61st European Renal Association (ERA) Congress, Fadi Fakhouri, MD, PhD, and others revealed results from NOBLE, a phase 2 trial comparing pegcetacoplan with standard of care in post-transplant patients with C3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (ICMPGN). C3G and ICMPGN are rare kidney diseases with no approved treatments, and they can lead to kidney failure within 5 to 10 years of diagnosis.

In an abstract, Dr. Fakhouri and his fellow researchers reported 12-week results showing that 60% of NOBLE participants treated with pegcetacoplan achieved reductions in C3c staining, activity score of C3G histology index, and proteinuria. They reported additional promising results from the 52-week point at the ERA Congress.

Pegcetacoplan in C3G and ICMPGN is also the subject of the phase 3 VALIANT study, which includes both patients with native kidney disease and those who have recurrent disease after a kidney transplant. Top-line results from that study are expected in mid-2024.

Dr. Fakhouri, a professor of nephrology at the Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland, spoke with Nephrology Times about the challenges of C3G and ICMPGN and the excitement around pegcetacoplan as a potential therapy.